Mycology Research Maitake MRL 500mg 90 tablets

Mycology Research Maitake MRL 500mg 90 tablets

Grifola frondosa is not an extract of Grifola frondosa, the powder does contain's both mycelium and primordia (young fruit body) cultivated into a biomass that is grown on a sterilised (autoclaved) substrate. This cultivation process ensures the powder is free from contamination by other fungi and that pesticides and heavy metals are absent. Grifola frondosa The cultivation system is proprietary, allowing for standardised production of Grifola frondosa. The powder biomass is then sealed in plastic containers.

Manufacturing Process of Maitake MRL Our Grifola frondosa is processed under the same rigorously controlled conditions that are applied to the manufacture of a conventional pharmaceutical. This ensures that each tablet contains 500 mg of the standardised Grifola product. The tablets are film coated to protect them from moisture, thus preserving the quality of the product and ensuring a long shelf life.
After passing quality control testing the tablets are released for use. The choice of additives used in manufacture renders these tablets suitable for Kosher or vegetarian use.

The Maitake-MRL biomass contains the mycelium and primordia (young fruiting body) of the mushroom grifola frondosa. In comparison to Maitake extracts, biomass has the advantage of no unwanted shift in effect which occurs with extracts or concentrates, including lyophilisation, and thus the activity of the product corresponds with the source mushroom. The biomass is certified organic in the United States. The biomass form allows for the mushroom enzymes and beta-glucans to be resistant to proteolytic enzymes found in the stomach.